Imitrex and Injection site warmth - a phase IV clinical study of FDA data

Summary:

Injection site warmth is reported as a side effect among people who take Imitrex (sumatriptan succinate), especially for people who are female, 40-49 old, also take Humira, and have Psoriatic arthropathy.

The phase IV clinical study analyzes which people have Injection site warmth when taking Imitrex. It is created by eHealthMe based on reports of 15,815 people who have side effects when taking Imitrex from the FDA, and is updated regularly.

What is Imitrex?

Imitrex has active ingredients of sumatriptan succinate. It is often used in migraine. eHealthMe is studying from 17,149 Imitrex users. Check the latest studies of Imitrex.

What is Injection site warmth?

Injection site warmth is found to be associated with 525 drugs and 699 conditions by eHealthMe. Check the latest studies of Injection site warmth.

On Jul, 19, 2026

15,815 people reported to have side effects when taking Imitrex.
Among them, 14 people (0.09%) have Injection site warmth.

Could Imitrex cause Injection site warmth?

Among these 14 people:

What is the gender of people who have Injection site warmth when taking Imitrex? *

female: 91.67 %
male: 8.33 %

What is the age of people who have Injection site warmth when taking Imitrex? *

What are other drugs people take besides Imitrex? *

What are other side effects people have besides Injection site warmth? *

Injection Site Erythema (redness at injection site): 12 people, 85.71%
Injection Site Swelling: 6 people, 42.86%
Injection Site Pruritus (severe itching at injection site): 5 people, 35.71%
Injection Site Urticaria (rash of round, red welts on the skin at injection site): 4 people, 28.57%
Injection Site Pain: 3 people, 21.43%
Nausea (feeling of having an urge to vomit): 3 people, 21.43%
Injection Site Reaction: 3 people, 21.43%
Rashes (redness): 3 people, 21.43%
Head Injury: 3 people, 21.43%
Injection Site Irritation: 2 people, 14.29%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 3 people, 21.43%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 3 people, 21.43%
Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 1 person, 7.14%
Headache (pain in head): 1 person, 7.14%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 7.14%
Birth Control: 1 person, 7.14%
Asthma: 1 person, 7.14%
Arthritis Enteropathic (form of chronic, inflammatory arthritis associated with the occurrence of an inflammatory bowel disease): 1 person, 7.14%
Ankylosing Spondylitis (type of arthritis affecting the spine): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Imitrex and have Injection site warmth?

- Check whether Injection site warmth is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Imitrex:

Imitrex (17,149 reports)

Browse all side effects of Imitrex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site warmth:

Injection site warmth (525 drugs)

Browse all the conditions that are associated with Injection site warmth:

Injection site warmth (699 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sumatriptan succinate (the active ingredients of Imitrex) and Imitrex (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.